Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
NCT05526560 · View on ClinicalTrials.gov ↗
Study Summary
Collect real-world data on acute and long-term safety and performance of the MITRIS RESILIA Mitral Valve, Model 11400M, in subjects requiring replacement of their native or prosthetic mitral valve with or without concomitant procedures.
Conditions Studied
Interventions
- DEVICE MITRIS RESILIA Mitral Valve, Model 11400M
Study Locations (20)
New York
- Mount Sinai Hospital — New York
- Columbia University Irving Medical Center — New York
- Weill Cornell Medicine — New York
Pennsylvania
- Hospital of the University of Pennsylvania — Philadelphia
- Allegheny General Hospital — Pittsburgh
- UPMC Presbyterian Shadyside — Pittsburgh
California
- Hoag Memorial Hospital Presbyterian — Newport Beach
- Stanford University — Palo Alto
Georgia
- Piedmont Heart Institute — Athens
- Piedmont Heart Institute — Atlanta
Tennessee
- Tristar Centennial Medical Center — Nashville
- Ascension Saint Thomas — Nashville
Florida
- AdventHealth Orlando — Orlando
Indiana
- Ascension St. Vincent Heart Center — Carmel
Michigan
- University of Michigan — Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 504 participants |
| Start Date | 2023-01-11 |
| Est. Completion | 2035-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05526560
The ClinicalTrials.gov registry entry for NCT05526560 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwards Lifesciences, which has 34 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Mitral Valve Insufficiency appearing as the primary indexed condition, and to 1 intervention — of which MITRIS RESILIA Mitral Valve, Model 11400M is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05526560 reports 20 study locations spanning 13 distinct geographic areas — top geographies include New York, Pennsylvania, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05526560 about?
NCT05526560 is a clinical study titled "Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve". Collect real-world data on acute and long-term safety and performance of the MITRIS RESILIA Mitral Valve, Model 11400M, in subjects requiring replacement of their native or prosthetic mitral valve with or without concomitant procedures.
What is the current status of trial NCT05526560?
This trial is currently active not recruiting. The enrollment target is 504 participants. The study started on 2023-01-11. Estimated completion is 2035-12.
What conditions does trial NCT05526560 study?
This clinical trial studies the following conditions: Mitral Valve Insufficiency, Mitral Stenosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05526560?
The interventions under investigation include: MITRIS RESILIA Mitral Valve, Model 11400M (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05526560?
This trial is sponsored by Edwards Lifesciences, which has 34 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05526560 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.